What is REMEDi4ALL?
Drug repurposing means finding new uses for existing medicines. Instead of developing new drugs, repurposing builds on existing knowledge of a drug’s safety, efficacy, and dosing, which allows for a potentially faster and more cost-effective route to new treatments.
REMEDi4ALL is an EU-funded initiative that aims to develop an accessible, standardised platform to provide the expertise, tools and resources required in all stages of the repurposing journey. REMEDi4ALL also hopes to build a global drug repurposing community and to generate a more favourable policy environment by identifying current barriers and exploring solutions.
What is a REMEDi4ALL Demonstrator Project?
To test the REMEDi4ALL platform’s viability and robustness we support real-world repurposing projects, known as ‘demonstrator projects’, covering infectious diseases, rare cancers, and rare/ultra rare diseases. Learn more about the REMEDi4ALL demonstrator projects.
The MOI-A Study: Repurposing Losartan for Osteogenesis Imperfecta (OI)
One of the demonstrator projects within Remedi4all is a study that aims to improve quality of life for people with Osteogenesis Imperfecta (OI), a rare bone condition, using a repurposed drug called Losartan. Losartan is already used to treat high blood pressure.
This study is called ‘MOI-A’ – which is an abbreviation of the full study title: Matrix-Directed Therapy In Older Adolescents And Adults With Osteogenesis Imperfecta.
You can find out more about the MOI-A study from Professor Nick Bishop and Professor Judith Cohen by watching the video below. Further information can also be found on the trial website.
REMEDi4ALL Partners & Associated partners
